150 related articles for article (PubMed ID: 33242523)
21. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Trichodysplasia Spinulosa-Associated Polyomavirus Capsid Protein as a New Carrier for Construction of Chimeric Virus-Like Particles Harboring Foreign Epitopes.
Gedvilaite A; Kucinskaite-Kodze I; Lasickiene R; Timinskas A; Vaitiekaite A; Ziogiene D; Zvirbliene A
Viruses; 2015 Jul; 7(8):4204-29. PubMed ID: 26230706
[TBL] [Abstract][Full Text] [Related]
23. The immunogenicity of the virus-like particles derived from the VP2 protein of porcine parvovirus.
Hua T; Zhang D; Tang B; Chang C; Liu G; Zhang X
Vet Microbiol; 2020 Sep; 248():108795. PubMed ID: 32827923
[TBL] [Abstract][Full Text] [Related]
24. Construction and Immunogenicity of Virus-Like Particles of Feline Parvovirus from the Tiger.
Jiao C; Zhang H; Liu W; Jin H; Liu D; Zhao J; Feng N; Zhang C; Shi J
Viruses; 2020 Mar; 12(3):. PubMed ID: 32188011
[TBL] [Abstract][Full Text] [Related]
25. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
26. [Construction and immunogenicity of recombinant porcine parvovirus-like particles with somatostatin].
Zhang X; Zheng Q; Chen J; Xue G; Hou H; Hou J
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1057-67. PubMed ID: 21090109
[TBL] [Abstract][Full Text] [Related]
27. Use of parvovirus-like particles for vaccination and induction of multiple immune responses.
Casal JI
Biotechnol Appl Biochem; 1999 Apr; 29(2):141-50. PubMed ID: 10075910
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of the newly identified human parvovirus 4 in the family Parvoviridae.
Lou S; Xu B; Huang Q; Zhi N; Cheng F; Wong S; Brown K; Delwart E; Liu Z; Qiu J
Virology; 2012 Jan; 422(1):59-69. PubMed ID: 22044541
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of adenovirus-derived porcine parvovirus-like particles displaying B and T cell epitopes of foot-and-mouth disease.
Pan Q; Wang H; Ouyang W; Wang X; Bi Z; Xia X; Wang Y; He K
Vaccine; 2016 Jan; 34(4):578-585. PubMed ID: 26685093
[TBL] [Abstract][Full Text] [Related]
30. Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan.
Chen MY; Yang SJ; Hung CC
Emerg Infect Dis; 2011 Oct; 17(10):1954-6. PubMed ID: 22000381
[TBL] [Abstract][Full Text] [Related]
31. Expression of Breast Cancer-Related Epitopes Targeting the IGF-1 Receptor in Chimeric Human Parvovirus B19 Virus-Like Particles.
Salazar-González JA; Ruiz-Cruz AA; Bustos-Jaimes I; Moreno-Fierros L
Mol Biotechnol; 2019 Oct; 61(10):742-753. PubMed ID: 31317318
[TBL] [Abstract][Full Text] [Related]
32. Recombinant Virus-like Particles of Human Parvovirus B19 with the Internal Location of VP1 Unique Region Produced by
Shao S; Wang Q; Jin Y; Zhang X; Liu Z; Chen S; Wu H; Yang S; Tang F; Su J; Liang Y; Zhang J; Li Q
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366508
[TBL] [Abstract][Full Text] [Related]
33. Occurrence of human bocaviruses and parvovirus 4 in solid tissues.
Norja P; Hedman L; Kantola K; Kemppainen K; Suvilehto J; Pitkäranta A; Aaltonen LM; Seppänen M; Hedman K; Söderlund-Venermo M
J Med Virol; 2012 Aug; 84(8):1267-73. PubMed ID: 22711355
[TBL] [Abstract][Full Text] [Related]
34. EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge.
Wang X; Xiao X; Zhao M; Liu W; Pang L; Sun X; Cen S; Yang BB; Huang Y; Sheng W; Zeng Y
BMC Res Notes; 2016 Jan; 9():42. PubMed ID: 26809443
[TBL] [Abstract][Full Text] [Related]
35. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses.
Sedlik C; Dridi A; Deriaud E; Saron MF; Rueda P; Sarraseca J; Casal JI; Leclerc C
J Virol; 1999 Apr; 73(4):2739-44. PubMed ID: 10074120
[TBL] [Abstract][Full Text] [Related]
36. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
[TBL] [Abstract][Full Text] [Related]
37. Analysis of two human parvovirus PARV4 genotypes identified in human plasma for fractionation.
Fryer JF; Delwart E; Bernardin F; Tuke PW; Lukashov VV; Baylis SA
J Gen Virol; 2007 Aug; 88(Pt 8):2162-2167. PubMed ID: 17622618
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection.
Yang SJ; Hung CC; Chang SY; Lee KL; Chen MY
J Clin Virol; 2011 May; 51(1):64-7. PubMed ID: 21353629
[TBL] [Abstract][Full Text] [Related]
39. Stability and integrity of self-assembled bovine parvovirus virus‑like particles (BPV‑VLPs) of VP2 and combination of VP1VP2 assisted by baculovirus-insect cell expression: a potential logistical platform for vaccine deployment.
Wubshet AK; Li GX; Li Q; Dai JF; Ding YZ; Zhou L; Qu M; Wang Y; Ma Z; Werid GM; Abera BH; Kebede AT; Sun Y; Yin X; Liu Y; Jie Z
Virol J; 2024 Apr; 21(1):87. PubMed ID: 38641833
[TBL] [Abstract][Full Text] [Related]
40. Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice.
Dai W; Xiong P; Zhang X; Liu Z; Chen J; Zhou Y; Ye X; Zhang C
Antiviral Res; 2019 Apr; 164():139-146. PubMed ID: 30817941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
